Member Info for alif

I think trials are ongoing subject to getting enough patients who meet eligibility criteria, (existing and a limited number of new patients.)

From US clinical trials site

Further study of GAM . 3 locations miami Florida, NYC, lincoln Nebraska

Last update -2026-06-08

https://clinicaltrials.gov/study/NCT06404034

IBAI is sponsor, collaborators : Xcures

We also need patience. GLA

Is this the co in dispute with Alba - Nord precious metals ?

if so this article mentions key phrases : Letter of Intent (LOI) and Non Binding.

Link :

https://rb.gy/vf67yo

In a nutshell :

FDA plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, the latest change from Trump administration officials vowing to speed up the availability of certain medical products.Going forward, the FDA’s “default position” will be to require one study for new drugs and other novel health products.

The announcement is the latest example of Makary and his team changing longstanding FDA standards and procedures

with the stated goal of slashing bureaucracy and accelerating the availability of new medicines.

From Apnews from a New England Journal of Medicine piece from a couple of days ago.

Positive news for us .

Dr Makary short CNBC interview on x/ twitr.

Says FDA needs to speed things up .

https://x.com/DrMakaryFDA

Light vs Heavy Rare Earths: Why the Distinction Matters - Interesting article on Alba Mineral Resources site .

https://shorturl.at/bHlF2

Https://greenrocplc.com/webinars

2025 Recap 2026 Outlook

Tomorrow 15 th 11am

Should be interesting ,at this point in our journey .

Al musella is still active within our company :

"Although Dr Musella will no longer serve on the IBAI Board, he will remain closely involved with IBAI's wholly owned subsidiary, Imaging Biometrics LLC in a more direct and frequent capacity."

"Dr Musella will assume the role of Medical Advisor, providing clinical insight and strategic input to product development and marketing efforts."

So, nothing negative here, in fact he has a more focused role within the company.

He is a valued asset and his Musella Foundation (for brain tumour research and information ) does great work in that field , which no doubt brings further valuable insights back into the lab.

GLA

Kirkstall’s Quasi Vivo® tech & its potential market.

The organ-on-a-chip U.S market is estimated at around USD 70M+ in 2024 and is projected to reach USD 940 + million by 2033, growing at a CAGR of 33.14% from 2025 to 2033.

The Global estimates are considerably larger - estimates are approx USD 215 billion in 2025 and are expected to reach around USD 3,242 billion by 2034, growing at a CAGR of about 35.15% during this period.

IBAI’s ecosystem will definately help Kirskstall’s products to reach a bigger target audience in both academic and medical/pharma worlds.

Its a good acquisition IMO with big potential .DYOR

Al

Key point :

Under the terms of the CLN, Truetide may not issue a conversion notice if doing so would result in Truetide, together with any persons deemed to be acting in concert with it (as defined in the UK Takeover Code), holding 30% or more of IBAI's issued share capital (as enlarged by such conversion).

Truetide holds a 29.35% interest in the IBAI.

So very unlikely that the CLN would be converted anytime soon.

However if IBAI share price was say 5p then some of the 29.35% holding (acquired at 1.1p) might be let go ….to make space for cln shares.

Lets see .

GLA

Some notes on Kirkstall (from various tweets direct from kirkstall & other sources)

Quasi Vivo® organ on a chip is a cost effective way to aid research.

It is an in-vitro model, plug‐and‐play, modular design lets you set up advanced 3D cell cultures in minutes.

Metastasis causes 90% of cancer deaths, yet remains incredibly hard to study because lab models can't accurately replicate tumour spread.

Built for Academia & Industry: Academics love the flexibility (run complex 3D cultures without a steep learning curve).

Industry loves the consistency (disposable 6-chamber trays for high-content screens , reproducible results).

One platform, tuned for all users.

Perfusion flow cell culture brings lab experiments closer to real-life conditions.

Ethical, reliable research without animal testing , the recently passed (Dec 22) FDA Modernization Act 2.0 (a bill that authorizes alternatives to animal testing and removes animal studies for biosimilar product ) is aligned with Kirkstall.

92% of drugs that pass animal tests fail in humans.

Big pharma companies testing new drugs can save considerable research costs time /money.

Kirkstall now has more exposure via the groundbreaking team at IBAI with its ever growing eco-system , so i think theres going to be some beneficial synchronity here.

Its a very positive move in my opinion.

Good luck all holders. DYOR

Al.

Dan Jørgensen's visit to Greenland and Amitsoq :

https://www.euractiv.com/news/eu-energy-chief-heads-to-greenland-amid-scramble-for-arctic-critical-minerals/

Link to the recent investor meet presentation with CEO Andy Bloomer & CFO Des Dimitrov :

https://www.youtube.com/watch?v=Cz6Y70DeN7M

IMO looking positive for the near future.

Al

Bertie: OMG- https://oxfordmetrics.com/

Like it !!!

Max & Bio,

I found this , the recently (Feb 2025) Re- introduced "Give Kids A Chance Act" calls for a time extension in section 5 , to Sept 30 2029 amongst other things, but i do not know how the Act is progressing etc.

https://childhoodcancer-mccaul.house.gov/media/press-releases/mccaul-reintroduces-landmark-childhood-cancer-legislation

Al

Stefan interview : https://www.youtube.com/watch?v=X0EGV7THssE

Shouston : Still no TR1 from institution who picked up 18m shares.

So possibly the 10m + 4m were sells. getting below notification 3% , plus raising £397k, which covers the warrant money (9m @ 3.75p =337.5k)

hopefully soon when s/p hits 5p.

just a guess on these Greenland Whale (Balaena mysticetus ) trades .

GLA

Some key points -

12 December 2024

UKHSA will be creating new partnerships with industry, academia, non-government organisations (NGOs) and other government bodies to prioritise the development of tests for pathogens with the greatest pandemic and epidemic potential, ensuring we have accurate diagnostic tests ready for infectious diseases that pose the greatest risk.

Currently, while UKHSA has developed its own in-house tests for a number of different pathogens including avian influenza and mpox, there is a lack of commercially available tests on the UK market that would allow testing to be ramped up to the levels needed for epidemic and pandemic scenarios for many infectious diseases.

Dame Professor Jenny Harries, UKHSA Chief Executive, said:

We are working constantly to ensure the right defences are in place for when the UK faces the next pandemic threat. Having world leading testing and diagnostic infrastructure in place is a critical part of this.

The Diagnostic Accelerator will help keep us at the forefront of innovation and ensure that the UK is a step ahead when it comes to tackling a wide range of pandemic and epidemic threats.

————————————————————

https://www.gov.uk/government/news/diagnostic-accelerator-launched-to-speed-up-pandemic-preparedness

Some main points i took from the ProActive Interview :

Michael Schmainda on GE partnership :

GE is major player .

Pricing model agreement is on a per scanner approach,theres alot of scanners in usa that are GE scanners.

Immediate market there with existing clients .

Leading to a step change in revenue from 2024 to 2025 in short timeframe

On Al Musella :

“Hes a man of action, he gets things done and thats exactly what we need right now ”

My take on the current situation:

Imaging Biometrics FTP mapping + Oral Gallium Maltolate treatment + Expanded Access Program = Higher Patient Success rate, leading to higher uptake of process (still in trials) .

The PPA ( Promising Pathway Act ) which Al musella and Senator Braun are pushing “ may possibly” be passed around jan 2025, helping to get FDA approval for Oral Gallium Maltolate treatment sooner (de-emphasising phase 3 trials)

This is the game changer for everyone .

Rome wasnt built in a day !

GLA & DYOR

Alif

Irish -

If theres a non payment in dec ,we still keep all cash paid thus far AND keep title to all the Kit - so limited down side.

Sure a quick sale would be preferred but...

Also why did Cantor Fitzgerald in Dublin buy 153,846,154 ? Are they a bit more positive about longer term potential .

Regards Alif

Part payment made : £60k.

Every bit helps !

GLA